⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IDYA News
IDEAYA Biosciences, Inc. Common Stock
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
prnewswire.com
IDYA
Form 8-K
sec.gov
IDYA
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
prnewswire.com
IDYA
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
prnewswire.com
IDYA
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
prnewswire.com
IDYA
Form 8-K
sec.gov
IDYA
IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer
prnewswire.com
IDYA
Form 8-K
sec.gov
IDYA
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO
prnewswire.com
IDYA
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com
IDYA